Go back to the main page.
Transforming Today's Science Into Tomorrow's Cures
Samaritan's collaborative researchers have made important patented discoveries in the fields of, central nervous system diseases, such as, Alzheimer's disease; cancer; cardiovascular disease; and infectious diseases, such as, AIDS, and Hepatitis C. These discoveries have positioned us with a rich pipeline of new drugs with novel mechanisms of actions to develop.
Samaritan Pharmaceuticals, Inc. is an entrepreneurial biopharmaceutical company focused on the development and marketing of innovative therapeutics. At Samaritan Pharmaceuticals our mission has been to create life-saving drugs for people suffering from AIDS, Alzheimer’s, heart disease and cancer. View all the latest press releases and news articles focused on Samaritan Pharmaceuticals, Inc. These publications, called peer-reviewed journals, are scholarly periodicals requiring each article submitted be judged by an independent panel of experts (scientific peers) to authenticate the accuracy of the material. The number of articles printed and the variety of publications accepting the article serve to underscore the legitimacy of information. Samaritan has collaborative relationships with other pharmaceutical companies to commercialize branded approved prescription products in selected niche territories, such as, in Greece, Albania, Bosnia, Bulgaria, Croatia, Cyprus, Czech Republic, Egypt, FYROM, Hungary, Montenegro, Poland, Romania, Serbia, Slovakia, Slovania, Syria and Turkey. Before a drug can be offered to the public it must go through several phases of rigorous testing to make sure it is safe, efficient and does what it says it can do. The testing is mandated and overseen by the U.S. Food and Drug Administration (FDA) which is part of the U.S. Department of Health and Human Services. SAMARITAN PIPELINE - (MECHANISM OF ACTION VIDEOS)
Go back to the main page. Contact Samaritan Pharmaceuticals, Inc. Find what you are looking for in our website.

HIV DRUG (SP-01A)
SP-01A (Sphirewall) Samaritan's HIV drug, is an oral viral entry inhibitor that was observed to have minimal toxic effect on human cells; and demonstrated significant efficacy in preventing viral replication of HIV virus strains resisting currently approved anti-HIV treatments. If used with any existing ARV, SP-01A creates a firewall around a healthy cell to prevent budding in and budding out. Learn More

HCV DRUG (SP-30)
A Novel Orally administered treatment for Hepatitus C, SP-30 is an oral alternative to current injectable formulas and has shown anti-viral activity for Hepatitis C in pre-clinical trials. Learn More

HIV DRUG (SP-10)
A Novel Orally administered treatment for HIV, SP-10 is an oral alternative to current injectable formulas and has shown anti-viral activity for HIV in pre-clinical trials. Learn More

 
SP-01A HIV DRUG
Oral Entry
Inhibitor Drug
SP-10 HIV DRUG
Small Molecule
Antiviral Adjuvant
SP-30 HIV DRUG
Small Molecule
Antiviral Adjuvant